Please login to the form below

Not currently logged in
Email:
Password:

HIV drug royalties sold for $160m

Vertex Pharmaceuticals has sold its rights to future royalties for two HIV drugs to GlaxoSmithKline
Vertex Pharmaceuticals has sold its rights to future royalties for two HIV drugs to GlaxoSmithKline (GSK).

Under the terms of the one-time cash payment, Vertex will not receive any royalties for future sales of HIV drugs Lexiva and Agenerase.

"The sale of this non-core financial asset provides us with significant capital and strengthens our financial position to support investment into key programs and future initiatives for our business," said Ian Smith, executive vice president and chief financial officer of Vertex Pharmaceuticals.

"In particular, this transaction will provide us with additional capital to support and advance our leadership position in hepatitis C drug development."

Vertex reported at the annual meeting of the European Association for the Study of the Liver (EASL) in April 2008 that results from early trials show that its hepatitis C drug, Telaprevir, used in combination with two other drugs, is a promising therapy.

6th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics